$2.11
-0.07 (-3.21%)
Open$2.18
Previous Close$2.18
Day High$2.18
Day Low$2.06
52W High$24.30
52W Low$2.00
Volume—
Avg Volume172.3K
Market Cap4.54M
P/E Ratio—
EPS$-9.28
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+684.4% upside
Current
$2.11
$2.11
Target
$16.55
$16.55
$10.07
$16.55 avg
$19.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 182.07M | 953.7K | 857.2K |
| Net Income | -29,966,016 | 90.7K | 81.5K |
| Profit Margin | -16.5% | 9.5% | 9.5% |
| EBITDA | -29,563,031 | 169.7K | 158.3K |
| Free Cash Flow | — | 104.6K | 58.4K |
| Rev Growth | +102.9% | +23.3% | +22.6% |
| Debt/Equity | — | 0.69 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |